What’s new in JPND?

Marta GomezJPND Management Board Member

19/02/2014

Joint Programming - a definition

European countries engaging

•voluntarily and on a variable geometry basis to tackle a major societal question

•in the definition, development and implementation of a common strategic research agenda

•based on a common vision on how to address major societal challenges.

We cannot tackle neurodegenerative diseases by acting as single countries

AlbaniaAustriaBelgiumCanadaCroatia

Czech RepublicDenmarkFinlandFrance

GermanyGreece

HungaryIrelandIsraelItaly

LuxembourgNetherlands

NorwayPoland

PortugalRomaniaSlovakiaSlovenia

SpainSweden

SwitzerlandTurkeyUnited

Kingdom

JPND is a global research initiative led by EU countries, with 28 participatingEU member statesAssociated countries Third countries

Increasing coordination of national research programmes to improve impact and effectiveness

JPND brings together….

• Researchers (Basic, Clinical, Healthcare/Social)

• National Funding Bodies

• National Research Strategies and Investments

Current JPND strategy

To increase coordinated investment in ND research

aimed at finding causes of disease, developing cures,

and identifying appropriate ways to care for those

with neurodegenerative diseases

• Immediate JPND goals:

• To add value to national investments through coordinated action

• To encourage the development of national research strategies in ND

• To engage in partnership to reach the full potential of JPND

JPND currently partly supported by FP7-JUMPAHEAD (GA. 260774)

Management Board • 27 countries represented• Members mandated to act• Chair Philippe Amouyel - France

Executive Board• Vice-Chair Adriana Maggi - Italy • Robin Buckle - UK• Mogens Horder - Denmark• Marlies Dorlochter - Germany

Scientific Advisory Board• 18 Members, chosen for scientific

excellence and competence

Organisation

Steering CommitteeExecutive Board + •Enda Connolly - Ireland •Rainer Girgenrath - Germany•Edvard Beem - Netherlands

DEFRAGMENTATION- WHAT JPND IS ALL ABOUT

STRATEGIC RESEARCH AGENDA

ALIGNMENT OF EU COUNTRIESON COMMON RESEARCH GOALS

Scientific• Animal models• Biobanks• Cohorts/registries• Disease pathology

Social• Health care delivery• Home automation• Health economics• Ethics

Medical• Early diagnosis• Prevention• Clinical trialsFocus on

Three Domains

Scope of the initiative

JPND Research Strategy (SRA)

• Agreed by 25 Member States + Assoc. Countries

• Officially Launched Feb 7th 2012

• Thematic priorities for future research:

• The origins of neurodegenerative disease

• Disease mechanisms and models

• Disease definitions and diagnosis

• Developing therapies, preventive strategies and interventions

• Healthcare and social care

How can JPND reach its goals?

•Alignment of research in Member Countries

•Partnership with the European Commission

•Partnership with Industry

•Partnership with other international organisations

•Involvement of Patients and Public

JPND Actions to date

• Common European Strategy

• Phase I SRA Implementation (2012-2014)

• Annual Transnational Calls for Proposals

• Action Groups

• National Plans and Strategies

• Communication + Dissemination

SRA Implementation (2012-2014)

Annual Calls for Proposals

Centres of Excellence in Neurodegeneration (CoEN)

•First call (2011) for € 6M – 8 projects

•Second call (2012-13) for € 8M – 5 “Pathfinder” projects

Year Total fund available

Research Area No. of Projects

2011(pilot)

€16M Optimization of biomarkers + harmonization of their use

4

2012 €18M Risk and Protective Factors 5

2012 €11M Evaluation of Healthcare 6

2013 €12M Cross-Disease Analysis open call

2013 €11M Preventive Strategies open call

Call Statistics

Biomarker call2011

Risk factor call2012

Healthcare2012

Nb of proposals submitted / nb of partners / budget requested

14 / 165 / 30.8 M€ 52 / 307 / 97 M€ 22 / 122 / 29 M€

Nb of proposals accepted / nb of partners / budget allocated

4 / 88 / 13.6 M€ 5 / 41 / 17 M€ 6 / 41 / 9 M€

Success rate 29% 10% 27%

Gender breakdown (partners) 23% 28% 42%

Total no. of proposals submitted = 88Total no. of partners involved = 594Overall success rate = 17%

SRA Implementation (2012-2014)

Action Groups

• To determine transnational research needs and opportunities

• Palliative Care (chair: E. Connolly)

• Animal and Cell Models (chair: A. Maggi)

• Assisted Living Technologies (chair J. Hoogendam)

• Longitudinal Cohort Studies (chair: R. Buckle)

• To promote engagement, commitment and partnerships

• Engagement and partnership with the EC (chair: P.

Amouyel)

• Engagement and Partnership with Industry (chair: A. Maggi)

• User and Public Involvement in ND Research (chair: M. Horder)

• Linkage + Alignment of National Plans and Initiatives (chair: E. Hirsch)

Action Group Recommendations

JPND-supported projects

Fact Sheets Publications

Monitoring & Evaluation

• JPND monitoring and evaluation framework

• Questionnaire on ‘attitudes towards JPND’

• External review of strategic direction + implementation

Stakeholder Engagement

Online Partnering Tool

Online Partnering Tool

Create Personal Profile Register Research Group

Online Partnering Tool

Register a proposal idea and form consortia online

Partnering Tool Pilot Phase

480User Profiles

550 User Profiles

(30 Countries)

550 User Profiles

(30 Countries)

Developing and Aligning ND research strategies

•Most JPND countries • No national roadmap • No identified priority actions in the field of ND research

•Those who do, take different approaches • Specific research programmes• National plans targeted to an individual disease (e.g. Dementia) • National plans comprising research, service delivery, both

•Since deciding to participate in JPND, an increasing number of countries are working towards developing SRAs

•Specific JPND actions aimed at encouraging countries to develop national research strategies in ND

Emerging national JPND-related activities

• The Netherlands• Research a major theme as part of National Deltaplan for Dementia

“…. the Deltaplan will follow closely the JPND strategic research agenda and will strengthen the international position of the Netherlands for both research and industry” Edith Schippers, Minister for Health, Welfare and Sport

• United Kingdom• David Cameron’s “Prime Minister’s challenge on dementia” includes

specific references to continued support for COEN and JPND research

• Ireland• National SRA developed to inform participation in JPND• Researchers using participation in 2011 JPND Biomarkers call to start

a national network in biomarkers for Alzheimer’s and Parkinson’s

Partnership with the European Commission

• First call of Horizon 2020 (Dec. 2013)• ERA-NET:

• “Establishing synergies between the Joint Programming on Neurodegenerative Diseases Research and Horizon 2020”.

• Proposal should:

• coordinate national and regional programmes for research in the area of ND diseases research by implementing a transnational call with EU co-funding

• promote the strategic alignment of research activities

• demonstrate the expected impact on national and transnational programmes as well as the leverage effect on European research and competitiveness

• plan the development of key indicators for supporting this.

• implement other joint activities including training and additional joint calls without EU co-funding.

Declaration from G8 summit on dementia

• In response, the OECD is launching a project in 2014 for research on Alzheimer’s and dementia:

• Aimed at strengthening international collaboration and promote data sharing at the international level.

• JPND invited to join the project Advisory Group

• OECD plans a G8 mapping based upon JPND mapping methodology

Keep up to date

• Visit the JPND website:• http://www.neurodegenerationresearch.eu• http://www.jpnd.eu

• Sign up to the JPND News Feeds

• Follow JPND Progress pages

• E-mail us: secretariat@jpnd.eu

• Follow us on Twitter:

@JPNDEurope